LivaNova - Page title

LivaNova PLC: TRANSACTION IN SHARES

Aug 2, 2016

2 August 2016

TRANSACTION IN OWN SHARES

LivaNova PLC (“LivaNova” or the “Company”) announces that its Board of Directors on 1 August 2016 approved the authorization of a share repurchase programme of up to $150 million (the “Share Repurchase Programme”.) The Share Repurchase Programme authorises the Company to repurchase up to $30 million of the Company’s ordinary shares from 1 September 2016 through 31 December 2016 and up to a total of $150 million (inclusive of the foregoing $30 million) between 1 September 2016 and 31 December 2018. The Share Repurchase Programme is in accordance with an authority approved by the Company’s shareholders at its annual general meeting on 15 June 2016. Purchases of the ordinary shares under the Share Repurchase Programme will be carried out on NASDAQ and will be notified to the market on the business day following the calendar day on which the repurchase occurred. Ordinary shares repurchased by the Company will be cancelled. Until further notice, the Share Repurchase Programme will be conducted pursuant to Rule 10b5-1 under the US Securities Exchange Act and may therefore continue during closed periods in accordance with applicable restrictions.

About LivaNova

LivaNova PLC is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The Company employs approximately 4,600 employees worldwide and is headquartered in London, U.K. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Surgery, Cardiac Rhythm Management, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.), respectively.

LivaNova is listed on NASDAQ and listed on the Official List of the UK’s Financial Conduct Authority and traded on London Stock Exchange (LSE) under the ticker symbol “LIVN”.

For more information, please visit www.livanova.com, or contact:

Investor Relations and Media
Karen King
Vice President, Investor Relations & Corporate Communications
Phone: +1 (281) 228-7262
Fax: +1 (281) 218-9332
e-mail: corporate.communications@livanova.com